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Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may improve
patient selection, response to therapy, and rational treatment designs. One approach to increase
this understanding involves detailed studies of exceptional responders: rare patients with
unexpected exquisite sensitivity or durable responses to therapy. We identified an exceptional
responder in a phase I study of pazopanib and everolimus in advanced solid tumors. Whole exome
sequencing of a patient with a 14-month complete response on this trial revealed two simultaneous
mutations in mTOR, the target of everolimus. In vitro experiments demonstrate that both
mutations are activating, suggesting a biological mechanism for exquisite sensitivity to everolimus
in this patient. The use of precision (or “personalized”) medicine approaches to screen cancer
patients for alterations in the mTOR pathway may help to identify subsets of patients who may
benefit from targeted therapies directed against mTOR.
INTRODUCTION
Genetic characterization of sensitivity to targeted anticancer therapies has led to
improvements in patient selection and treatment of multiple tumor types, including lung
adenocarcinoma, colorectal adenocarcinoma, breast adenocarcinoma, and melanoma(1).
Identification of patients with exquisite sensitivity and/or durable responses to targeted
therapies – so called “exceptional responders” – may lead to improved patient selection and
allow for more rational treatment designs.
Single-agent therapy for cancer only rarely results in durable disease control. At the same
time, toxicities from therapeutic combinations often produce unacceptable toxicities(2).
Therefore, careful pharmacokinetic investigation is needed during phase I studies to
determine which combination therapies should be considered for further evaluation. VEGF
receptor tyrosine kinase inhibitors (TKIs) often exhibit significant side effects, including
rash, diarrhea, proteinuria, endocrine abnormalities, cardiotoxicity, and fatigue(3). Of these
TKIs, pazopanib may be associated with less toxicity yet comparable efficacy(4–6). The
lower toxicity and demonstrable activity of pazopanib make it an appealing candidate to
combine with other targeted therapies. Inhibiting the PTEN/Akt/mTOR pathway by
everolimus may complement VEGF receptor inhibition. Activation of mTOR, a downstream
effector of Akt, has been shown in preclinical models to increase tumor cell proliferation
and promote angiogenesis. Everolimus, an oral inhibitor of mTOR, decreases tumor and
endothelial cell proliferation and tumor cell VEGF production, leading to antitumor and
potential anti-angiogenic effects. Combining mTOR inhibitors with angiogenesis inhibitors
in preclinical studies has been shown to augment both anti-angiogenic and antitumor
effects(7, 8), suggesting that these two classes of agents might comprise an effective
therapeutic combination.
Here, we describe the results of a phase I study of pazopanib and everolimus in advanced
solid tumors. In this study, one patient with platinum- and taxane-refractory urothelial
carcinoma experienced a complete radiologic response that lasted for 14 months. To
elucidate the underlying mechanism of this extraordinary response, whole exome
sequencing of tumor and normal DNA from this patient was performed.
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RESULTS
Patients
Patient characteristics and the details of treatment are summarized in Table 1. Nine patients
were enrolled in this trial (5 with urothelial carcinoma, 1 with small cell lung carcinoma
(SCLC), 1 with non-small cell lung carcinoma (NSCLC), 1 with atypical carcinoid tumor of
the lung, and 1 with adrenocortical carcinoma). All patients had experienced disease
progression on standard therapies. The median number of cycles completed was 4 (range 1–
13). Of the five patients with urothelial carcinoma, 1 patient received therapy for 13 cycles
(28-day cycles; see Methods) and another for 6 cycles. Two patients completed 4 cycles, and
one patient came off after the first cycle due to toxicity. The patient with NSCLC came off
study after 2 cycles for toxicity and the patients with SCLC and atypical carcinoid tumor
came off study for progression after 2 cycles. The patient with adrenocortical carcinoma
completed 13 cycles of therapy and came off study per physician decision.
Safety
Two patients on pazopanib 600 mg daily and everolimus 5 mg daily experienced dose
limiting toxicities (one grade 3 rash and pruritus and one grade 3 thrombocytopenia
requiring a dose reduction) leading to dose de-escalation. Three patients were treated with
pazopanib 400 mg daily and everolimus 5 mg daily. Since none of the first three patients
experienced a protocol-defined dose-limiting toxicity, pazopanib 400 mg daily plus
everolimus 5 mg daily, anadditional 3 patients were treated at the MTD. Pazopanib 400 mg
daily plus everolimus 5 mg daily was defined as the maximum tolerated dose (MTD).
Throughout the study, 5 of 9 treated patients experienced grade 3 or higher treatment-related
toxicity (56%; 95% CI: 21.2%–86.3%). Hematologic toxicities during this trial included
grade 3 febrile neutropenia and thrombocytopenia, each in 1 patient. Non-hematologic
toxicities were varied, though many were expected based on the known toxicities of
everolimus and pazopanib. One patient experienced a grade 3 pneumothorax, considered
possibly related to study therapy. Other non-hematologic toxicities included anorexia (1
patient), bone pain (1 patient), diarrhea (2 patients; 1 patient with grade 3), fatigue (5
patients), dysgeusia (1 patient), headache (1 patient), hypertension (2 patients), mucositis (3
patients), musculoskeletal (muscle stiffness after prolonged periods of sitting, 1 patient),
nausea (4 patients), palmo-plantar erythrodysesthesia syndrome (2 patients), pneumonia (1
patient, grade 3), pruritus (1 patient, grade 3), rash (3 patients, 1 patients with grade 3),
vomiting (3 patients), and weight loss (1 patient). Toxicities noted in laboratory evaluations
were generally consistent with what is expected with both agents administered separately.
Grade 3 and 4 laboratory toxicities included increased ALT, hypophosphatemia, and
hypouricemia each in 1 patient, and increased lipase in 2 patients. All toxicities are
summarized in Supplementary Tables 1 and 2.
Pharmacokinetics
Mean steady-state pharmacokinetic variables for everolimus in 7 patients and pazopanib in 6
patients, the MTD of the combination, are presented in Supplementary Table 3. Mean values
of these parameters for the same dose and schedule of both drugs given alone in prior phase
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I trials are shown in the table for comparison. The mean pharmacokinetic variables for
pazopanib were in excellent agreement with data reported for a 400 mg daily dose given as a
single agent(9). In contrast, the mean AUC24ss of everolimus given concurrently with
pazopanib was 41% greater than the mean value reported for a 5 mg daily dose given alone.
These findings suggest that the pharmacokinetics of pazopanib are unaffected by everolimus
whereas the apparent oral clearance of everolimus is markedly diminished by pazopanib,
resulting in increased concentrations of the drug in whole blood, when the two agents were
given together on a continuous basis.
Antitumor activity
One patient with metastatic urothelial carcinoma experienced a complete radiographic
response that lasted for 14 months (Figure 1, A–D). Of the other urothelial carcinoma
patients who were evaluable for responses, 3 had stable disease for 3.8 months, 5.6 months
and 3.8 months respectively (Table 1). The patient with adrenocortical carcinoma also
experienced prolonged stable disease for 13 months.
Whole-exome sequencing
To identify possible genetic mechanisms of sensitivity to everolimus/pazopanib in the
patient with a complete radiographic response, we performed whole exome sequencing of
the pre-treatment tumor and germline DNA from this patient. The DNA was sequenced to a
mean depth of coverage of 74X (tumor) and 90X (normal), respectively. The coding regions
from a total of ~25,000 genes were sequenced, with at least 80% of exons achieving 20X
coverage or greater. 570 somatic single nucleotide variants (SNVs) were identified, of which
340 were missense, nonsense, or splice-site mutations (Supplementary Table 4). Of these
340 alterations, 5 were in genes in the Cancer Gene Census (CGC), a curated catalogue of
genes for which mutations have been causally implicated in cancer: PCM1, RANBP17,
CTNNB1, FANCA, and TP53. Two of the 340 SNVs are present in the Catalogue of Somatic
Mutations in Cancer (COSMIC)( 10), a database of somatic mutations found in human
cancer: CTTNB1 at an allelic fraction (AF) of 49% and TP53 at an AF of 70%. There were
377 somatic small insertions or deletions (indels), of which 143 occurred in coding regions
or at splice sites. Of these 143 indels, 8 were in CGC genes: PDGFRA, ATRX, NUP214,
CEBPA, MLL, MLL2, ARID1A, KDM6A (UTX). Indels in PDGFRA, ATRX, NUP214, and
CEBPA were all present at an AF of < 10%.
Examination of the sequencing data for biologically plausible mechanisms of sensitivity to
everolimus or pazopanib revealed two mutations in mTOR, the target of everolimus (Figure
2). Although 96 somatic nonsynonymous mutations in mTOR have been reported in the
COSMIC database to date, neither mutation identified in this patient has been previously
reported in human cancer. One mutation, mTORE2419K (AF 51%) (Figure 2A), is a well-
described activating mutation in the kinase domain of mTOR, even though not identified in
human cancer to date(11). The homologue of this mutation was identified in a fission yeast
screen to identify single amino acid changes in yeast Tor2 (the fission yeast homologue of
mTOR) that can cause hyperactivation of the pathway. There, a single mutation in Tor2,
E2221K, was identified that conferred constitutive activation of TOR. The homologous
mutation in human mTOR, E2419K, was subsequently generated in human cell lines and
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shown to be constitutively activating through increased kinase activity and hyperactivation
of the mTOR pathway. Notably, mTOR-mediated signaling remained sensitive to rapamycin
in cells expressing mTORE2419K (11).
The second mutation we identified, mTORE2014K (AF 52%) (Figure 2B), occurs in the
FKBP-rapamycin-binding (FRB) domain of mTOR. It has not been previously reported in
clinical tumor samples, though it is present in the urothelial cancer cell line U-BLC1(12). In
another study of potential hyperactivating mutations in mTOR, 2 FRB mutations, I2017T
and A2020V, were shown to enhance kinase activity and cause hyperactivation of the
mTOR pathway. Moreover, a mutant mTOR with both E2419K and I2017T exhibited higher
activity of mTOR as compared to each individual mutation(13).
Functional assessment of MTOR mutations
To confirm that these mutations are activating, we assessed them using an established
mTOR activity assay(11). Each mutant was individually overexpressed in HEK-293T cells
and assayed for the degree of phosphorylation of S6K1, a downstream substrate of mTOR.
As shown in Figure 2C, overexpression of mTORE2419K or mTORE2014K individually
resulted in increased phosphorylation of S6K1 as compared to wildtype mTOR (Figure 2C,
lanes 4 and 7 compared with lane 1). To determine if these mutations might exert additive
activating effects, a variant of mTOR harboring both mutations was generated.
Overexpression of this double mutant resulted in greater phosphorylation of S6K1 than did
either single mutant (Figure 2C, lane 10 compared with lanes 4 and 7).
The mTOR residues E2014 and E2419 are conserved throughout all eukaryotic TOR genes.
E2014 is located in a long helix that directly precedes the FRB domain (Figure 3, top
magenta), termed the kα1 helix(14). This helix is common to both mTOR and PI3 kinases
and is important for the structural integrity of the kinase domain N-terminal lobe(14). E2419
(Figure 3, bottom magenta) is located near the negative regulatory domain, unresolved in the
shown model. Though functional experiments show E2014K and E2419K to be activating
mutations, neither make contact with the mTOR activation loop (Figure 3, light yellow) and
thus are not likely to directly change its conformation. Similarly, neither mutation interfaces
directly with bound rapamycin (Figure 3, cyan), and therefore would not be likely to directly
alter binding to rapamycin or everolimus.
To test this, HEK-293T cells overexpressing wildtype or mutant mTOR were treated with
rapamycin and the effect on S6K1 phosphorylation was assessed. As shown in Figure 2C,
treatment with 0.1 μM rapamycin completely abrogated S6K1 phosphorylation by both
wildtype and mutant mTOR, suggesting that these mutations remain highly sensitive to
allosteric inhibition. In contrast, S6K1 phosphorylation was not affected by 1.0 μM
pazopanib, though treatment with 10 μM pazopanib did diminish phosphorylation of S6K1
(Supplementary Figure 1).
Taken together, these results are consistent with the notion that the occurrence of two
activating mTOR mutations within the same bladder tumor might contribute to an exquisite
dependency on mTOR signaling and therefore an exceptional response to mTOR inhibition.
Although it is possible that these two mutations occurred independently in different cells
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(each independently conferring sensitivity to a different subset of the tumor cells), the fact
that both occurred with an AF of ~50% is highly suggestive that these mutations were
heterozygous and were both present simultaneously throughout this tumor sample.
While we cannot rule out a direct contribution from pazopanib to the exquisite sensitivity in
this patient, the doses of pazopanib required to overcome the effects of these mTOR
mutations were more than 100-fold higher than those for rapamycin. Moreover, we were
unable to identify any additional genomic alterations that might suggest a mechanism of
pazopanib sensitivity. Although PDGFRA is a target of pazopanib, the indel identified in
this gene (p.Y102fs) was detected at an AF of 2%, and is therefore unlikely to be
functionally relevant in this tumor.
DISCUSSION
This phase I study of everolimus and pazopanib in patients with advanced solid tumors
demonstrates that everolimus and pazopanib must be combined at doses 50% lower than
their standard doses (pazopanib 400 mg and everolimus 5 mg daily). This is consistent with
a pharmacokinetic drug interaction that decreases the apparent oral clearance of everolimus
when combined with pazopanib, resulting in higher than expected concentrations of the drug
in whole blood. The most common toxicities associated with therapy included fatigue,
nausea, vomiting, diarrhea, and rash. In this study, several patients experienced prolonged
stable disease. One patient with chemotherapy-refractory urothelial carcinoma demonstrated
a complete radiographic response that lasted for more than one year. Only one other patient
(with adrenocortical carcinoma) experienced a meaningful clinical benefit (stable disease for
13 months). Whole exome sequencing revealed the presence of 2 simultaneous activating
mTOR mutations in the urothelial carcinoma tumor sample, suggesting a biological
mechanism for exquisite sensitivity to everolimus in this patient.
In principle, tumors that exhibit a dependency on the mTOR pathway might be expected to
show enhanced sensitivity to mTOR inhibition with drugs such as everolimus. Such
dependencies could, conceivably, occur though any activating genomic alterations involving
the mTOR pathway. In hamartoma syndromes such as tuberous sclerosis complex and
Peutz-Jeghers Syndrome, inactivating mutations in the tumor suppressor genes TSC1, TSC2,
and STK11 (LKB1) result in mTOR pathway activation and are targetable by TOR
inhibitors(15–17). Similarly, a study describing 3 patients with malignant perivascular
epithelioid cell tumors (PEComas) who had a significant clinical response to sirolimus
demonstrated that two of these patients lacked expression of TSC2 and one patient had
biallelic deletion of TSC1, suggesting that TSC1/2 loss may predict sensitivity to mTOR
inhibition in PEComas(18). In a recent phase II study of everolimus in chemotherapy
refractory urothelial carcinoma, whole genome sequencing of a single patient who had a
durable complete remission was found to have somatic TSC1 mutation (along with a
somatic NF2 mutation)(19). In addition, four of five additional patients with TSC1
mutations experienced tumor shrinkage with everolimus on that trial. However, beyond loss
of TSC1/2, the basis for sensitivity to mTOR inhibition in cancer remains incompletely
understood.
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Here, we describe the first activating mutations in mTOR found in a patient tumor that was
exquisitely sensitive to mTOR inhibition. One of these constitutively activating mutations,
mTORE2419K, had previously been evaluated in human tissue culture based on its homology
to an activating mutation observed in yeast(11). Though well studied in vitro, this mutation
has not heretofore been identified in human tumors. Similarly, the second mutation,
mTORE2014K, has not previously been described. Indeed, very few activating mTOR
mutations in human tumors have been described(20). In the COSMIC database, there are 96
confirmed somatic nonsynonymous mutations in MTOR from 106 tumor samples. Recurrent
mutations include R2505P (N = 4), S2215Y (3), E1799K (2), T1977R (2), L1433S (2),
C1483F (2), and L1460P (2). To date, 3 of these mTOR mutations found in human tumors
have been shown to be activating in vitro. L1460P was identified as an activating mutation
along with E2419K via the aforementioned fission yeast screen(11). More recently,
additional mutations present in the COSMIC database were tested, and S2215Y and R2505P
were shown to be activating in vitro. Notably, all 3 of these mutations remain sensitive to
rapamycin exposure in vitro, though clinical information regarding the patients from whom
these mutations were isolated is not available.
An additional mTOR mutation, L2431P, was recently identified in a patient with metastatic
renal cell carcinoma and shown to be activating in vitro(21). This kinase domain mutation
was present in the majority of the samples taken from the primary tumor but absent from the
metastatic biopsies. After 6 weeks of treatment with everolimus, imaging did not reveal any
change in the dimensions of the primary tumor; this primary tumor was then surgically
removed. Although this tumor did not apparently respond to a relatively short exposure to
everolimus, it is not clear if this mutation is sensitive to allosteric inhibition of mTOR, in
contrast to the mutations described in this study. Moreover, if the mTOR mutation detected
in the renal cell carcinoma was present at a low allelic fraction, a clinical response may not
have been apparent. The case described here provides evidence that activating mTOR
mutations can confer clinically significant sensitivity to mTOR inhibition. Further clinical
studies are needed to determine the specific circumstances under which patients with
mTOR-mutated tumors are most likely to respond to mTOR inhibition.
Multiple activating alterations in the mTOR pathway, including mTOR, TSC1/2, and
STK11 (LKB1), have now been shown to confer sensitivity to clinical mTOR inhibition.
Systematic functional analysis of mutations in mTOR, as well as other members of the
mTOR pathway, may help to identify activating mutations a priori, generating a catalogue
of activating mTOR-pathway alterations that may predict sensitivity to mTOR inhibition.
Furthermore, routine screening of cancer patients for these alterations may help to identify a
subset of patients who may respond to targeted therapies against mTOR, including
everolimus and other rapamycin analogues as well as direct mTOR kinase inhibitors now in
clinical trials.
More generally, the study of extraordinary responses in patients with cancer has the
potential to identify novel genomic and molecular mechanisms of sensitivity to many
different anticancer therapies. The ultimate goal of such an approach is to use those
mechanisms for prospective identification of patients who might similarly respond to those
specific therapies. Though promising, this approach also several challenges for precision
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medicine going forwards. First, for each new plausible mechanism of extraordinary response
identified, it may become important to characterize not only the functional significance of
such alterations, but also whether the tumors in which they occur are truly dependent on the
alterations. Because it is often difficult to recreate a dependency (and therefore sensitivity to
a particular agent) in experimental models, the generation of patient-derived cell lines or
patient-derived xenografts may eventually enable more definitive assessments of
dependencies linked to specific genomic alterations in patients with the potential to be
exceptional responders to anticancer agents.
It has become increasingly clear that the spectrum of actionable cancer gene alterations
exhibits a “long tail” pattern, in which the vast majority of cancer genes are mutated at
frequencies of <5% within any given histologic tumor subtype(1, 22). Since many such
cancer genes and mutations remain undiscovered, the implication is that a large number of
mutations in putatively actionable genes identified through tumor mutation profiling for
precision medicine will never have been observed before. In the future, therefore, greater
flexibility will be needed in the design of genomically-driven clinical trials to allow for a
broad range of pathway alterations and to enroll small numbers of patients with less
common mutations. Such innovations should enable more robust testing of many hypotheses
generated by studies of exceptional responders and more rapid discovery of features that
predict major clinical responses to anticancer agents.
METHODS
Phase I clinical trial
Patients ≥ 18 years old with metastatic or unresectable solid tumors for which standard
curative or palliative measures do not exist, are not tolerable, or are no longer effective were
eligible to enroll in this study. Detailed eligibility criteria can be found in the Data
Supplement. This study was conducted with institutional review board approval in
accordance with the Declaration of Helsinki and Good Clinical Practice and was registered
with the National Institutes of Health (NCT01184326). Each patient provided written
informed consent.
Study design
The primary endpoint of the study was to determine the maximum tolerated dose (MTD)
and dose limiting toxicities (DLT) of combination therapy with everolimus and pazopanib.
A standard 3 + 3 design was used starting with pazopanib 600 mg and everolimus 5 mg
given orally once daily on a continuous basis during a 28-day cycle. The dose escalation was
planned to alternate sequential escalations up to pazopanib 800 mg daily and everolimus 10
mg daily, or de-escalation to pazopanib 400 mg daily and everolimus 5 mg daily. Safety
evaluation methodology is detailed in the Data Supplement.
Pharmacokinetics
Pharmacokinetic sampling was performed on day 15 of the first cycle of therapy to insure
that steady-state conditions for the repeated dosing schedule for both drugs had been
achieved. Blood specimens were obtained before initiating treatment, immediately before
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dosing on day 15, at 1, 2, 4 and 6 hours after dosing, and before dosing on the following
day. Detailed pharmacokinetic methology can be found in the Data Supplement.
Efficacy
Objective tumor response, progression-free survival, and duration of response were
evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) Committee v.
1.1(23).
Whole Exome Sequencing
Sequencing studies were approved by the Dana-Farber/Harvard Cancer Center Institutional
Review Board, and written informed consent was obtained from the patient. Whole exome
sequencing was performed on the normal blood and tumor sample as detailed in the Data
Supplement. The mean depth of coverage from the blood and tumor sample were 90- and
76-fold, respectively. Sequencing data were analyzed using tools to identify somatic point
mutations and small insertions/deletions (indels) using established algorithms (see Data
Supplement). Detailed analyses of all sequencing results are available in the Data
Supplement (Supplementary Table 4).
Experimental Analysis
Expression plasmids containing mTOR were obtained and site-directed mutagenesis was
performed as detailed in the Data Supplement. Transfections, mTOR activity assay, and
immunoblot studies were performed using standard protocols (see Data Supplement).
Authentication of HEK-293 cells was not performed. Physical and biologic containment
procedures for recombinant DNA followed institutional protocols in accordance with the
National Institutes of Health Guidelines for Research Involving Recombinant DNA
Molecules.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF SIGNIFICANCE
The study of exceptional responders represents a promising approach to better
understand the mechanisms that underlie sensitivity to targeted anticancer therapies.
Here, we identify two activating mTOR mutations in a patient with exquisite sensitivity
to everolimus and pazopanib, suggesting an approach to identifying patients who might
benefit most from mTOR inhibitors.
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Figure 1. A 70 year-old man with metastatic urothelial carcinoma with a 14-month complete
response to everolimus and pazopanib
Prior to the start of treatment, axial (a) and coronal (b) CT images without intravenous
contrast demonstrate retroperitoneal adenopathy in left paraaortic and retrocaval stations
(white arrows). Follow-up non-contrast axial (c) and coronal (d) CT images obtained two
months after the start of therapy demonstrate resolution of the pathologically enlarged
retroperitoneal lymph nodes (yellow arrows).
Wagle et al. Page 13
Cancer Discov. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Identification of two activating mTOR mutations in a patient with a complete response
to everolimus and pazopanib
(a–b) Representative genome images from the Integrated Genome Viewer (IGV) for two
alterations in MTOR found in found in a patient with urothelial cancer who had a complete
response to everolimus and pazopanib. The number of reads for the reference allele and the
variant allele are shown for each alteration. (c) Effect of overexpression of mutant mTOR on
phosphorylation of the downstream target S6K1. Constructs expressing mTORE2014K,
mTORE2419K, mTORE2014K/E2419K, or wildtype mTOR were co-expressed in HEK-293T
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cells with HA-GST-tagged S6K1. The levels of both endogenous and exogenously
expressed phosphorylated and total S6K1 as well as Flag-tagged-mTOR and GAPDH are
shown for HEK-293T cells expressing the MTOR mutations after a 6-hour incubation at 0
μM, 0.1 μM, or 1.0 μM rapacycin as indicated.
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Figure 3. Structural model of mTORE2014K and mTORE2419K
Cartoon representation of the mTORΔN-mLST8-rapamycin-FKBP12 model with color-
coded domains. mTor residues E2014 and E2419 are indicated in magenta, with side chains
shown as spheres. The model was created by superposing the FRB domains of the FRB-
rapamycin-FKBP12(24) and the mTORΔN-mLST8 structures(14). mLST8 is a requisite
component of mTOR complex 1 and 2.
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